BACKGROUND: Epidemiologic research suggests that increased cancer risk due to chronic arsenic exposure persists for several decades even after the exposure has terminated. Observational studies suggest that antioxidants exert a protective effect on arsenical skin lesions and cancers among those chronically exposed to arsenic through drinking water. This study reports on the design, methods and baseline analyses from the Bangladesh Vitamin E and Selenium Trial (BEST), a population-based chemoprevention study conducted among adults in Bangladesh with visible arsenic toxicity. MATERIALS AND METHODS: Bangladesh Vitamin E and Selenium Trial is a 2 × 2 full factorial, double-blind, randomized controlled trial of 7000 adults having manifest arsenical skin lesions evaluating the efficacy of 6-year supplementation with alpha-tocopherol (100 mg daily) and L-selenomethionine (200 μg daily) for the prevention of nonmelanoma skin cancer. RESULTS: In cross-sectional analyses, we observed significant associations of skin lesion severity with male gender (female prevalence odds ratio (POR) = 0.87; 95% CI = 0.79-0.96), older age (aged 36-45 years, POR = 1.27; 95% CI = 1.13-1.42; aged 46-55 years, POR = 1.44; 95% CI = 1.27-1.64 and aged 56-65 years, POR = 1.50; 95% CI = 1.26-1.78 compared with aged 25-35 years), hypertension (POR = 1.29; 95% CI = 1.08-1.55), diabetes (POR = 2.13; 95% CI = 1.32-3.46), asthma (POR = 1.55; 95% CI = 1.03-2.32) and peptic ulcer disease (POR = 1.20; 95% CI = 1.07-1.35). CONCLUSIONS: We report novel associations between arsenical skin lesions with several common chronic diseases. With the rapidly increasing burden of preventable cancers in developing countries, efficient and feasible chemoprevention study designs and approaches, such as employed in BEST, may prove both timely and potentially beneficial in conceiving cancer chemoprevention trials in Bangladesh and beyond.
RCT Entities:
BACKGROUND: Epidemiologic research suggests that increased cancer risk due to chronic arsenic exposure persists for several decades even after the exposure has terminated. Observational studies suggest that antioxidants exert a protective effect on arsenical skin lesions and cancers among those chronically exposed to arsenic through drinking water. This study reports on the design, methods and baseline analyses from the Bangladesh Vitamin E and Selenium Trial (BEST), a population-based chemoprevention study conducted among adults in Bangladesh with visible arsenic toxicity. MATERIALS AND METHODS: Bangladesh Vitamin E and Selenium Trial is a 2 × 2 full factorial, double-blind, randomized controlled trial of 7000 adults having manifest arsenical skin lesions evaluating the efficacy of 6-year supplementation with alpha-tocopherol (100 mg daily) and L-selenomethionine (200 μg daily) for the prevention of nonmelanoma skin cancer. RESULTS: In cross-sectional analyses, we observed significant associations of skin lesion severity with male gender (female prevalence odds ratio (POR) = 0.87; 95% CI = 0.79-0.96), older age (aged 36-45 years, POR = 1.27; 95% CI = 1.13-1.42; aged 46-55 years, POR = 1.44; 95% CI = 1.27-1.64 and aged 56-65 years, POR = 1.50; 95% CI = 1.26-1.78 compared with aged 25-35 years), hypertension (POR = 1.29; 95% CI = 1.08-1.55), diabetes (POR = 2.13; 95% CI = 1.32-3.46), asthma (POR = 1.55; 95% CI = 1.03-2.32) and peptic ulcer disease (POR = 1.20; 95% CI = 1.07-1.35). CONCLUSIONS: We report novel associations between arsenical skin lesions with several common chronic diseases. With the rapidly increasing burden of preventable cancers in developing countries, efficient and feasible chemoprevention study designs and approaches, such as employed in BEST, may prove both timely and potentially beneficial in conceiving cancer chemoprevention trials in Bangladesh and beyond.
Authors: Giovanni Leonardi; Marie Vahter; Felicity Clemens; Walter Goessler; Eugen Gurzau; Kari Hemminki; Rupert Hough; Kvetoslava Koppova; Rajiv Kumar; Peter Rudnai; Simona Surdu; Tony Fletcher Journal: Environ Health Perspect Date: 2012-01-31 Impact factor: 9.031
Authors: Yu-Hsuan Shih; Tariqul Islam; Samar Kumar Hore; Golam Sarwar; Mohammad Hasan Shahriar; Mohammad Yunus; Joseph H Graziano; Judith Harjes; John A Baron; Faruque Parvez; Habibul Ahsan; Maria Argos Journal: Environ Res Date: 2017-08-01 Impact factor: 6.498
Authors: Jianjun Gao; Shantanu Roy; Lin Tong; Maria Argos; Farzana Jasmine; Ronald Rahaman; Muhammad Rakibuz-Zaman; Faruque Parvez; Alauddin Ahmed; Samar K Hore; Golam Sarwar; Vesna Slavkovich; Mohammad Yunus; Mahfuzar Rahman; John A Baron; Joseph H Graziano; Habibul Ahsan; Brandon L Pierce Journal: Environ Res Date: 2014-11-25 Impact factor: 6.498
Authors: Gurleen Kaur; Karan P Desai; Isabella Y Chang; Jonathan D Newman; Roy O Mathew; Sripal Bangalore; Ferdinand J Venditti; Mandeep S Sidhu Journal: Cardiovasc Drugs Ther Date: 2022-01-14 Impact factor: 3.727
Authors: Maria Argos; Faruque Parvez; Mahfuzar Rahman; Muhammad Rakibuz-Zaman; Alauddin Ahmed; Samar Kumar Hore; Tariqul Islam; Yu Chen; Brandon L Pierce; Vesna Slavkovich; Christopher Olopade; Muhammad Yunus; John A Baron; Joseph H Graziano; Habibul Ahsan Journal: Epidemiology Date: 2014-07 Impact factor: 4.822
Authors: Maria Argos; Lin Tong; Brandon L Pierce; Muhammad Rakibuz-Zaman; Alauddin Ahmed; Tariqul Islam; Mahfuzar Rahman; Rachelle Paul-Brutus; Ronald Rahaman; Shantanu Roy; Farzana Jasmine; Muhammad G Kibriya; Habibul Ahsan Journal: J Med Genet Date: 2014-03-24 Impact factor: 6.318
Authors: Catherine M Bulka; Molly Scannell Bryan; Victoria W Persky; Martha L Daviglus; Ramon A Durazo-Arvizu; Faruque Parvez; Vesna Slavkovich; Joseph H Graziano; Tariqul Islam; John A Baron; Habibul Ahsan; Maria Argos Journal: Environ Pollut Date: 2019-02-07 Impact factor: 9.988
Authors: Dayana A Delgado; Chenan Zhang; Kevin Gleason; Kathryn Demanelis; Lin S Chen; Jianjun Gao; Shantanu Roy; Justin Shinkle; Mekala Sabarinathan; Maria Argos; Lin Tong; Alauddin Ahmed; Tariqul Islam; Muhammad Rakibuz-Zaman; Golam Sarwar; Hasan Shahriar; Mahfuzar Rahman; Muhammad Yunus; Jennifer A Doherty; Farzana Jasmine; Muhammad G Kibriya; Habibul Ahsan; Brandon L Pierce Journal: Hum Genet Date: 2018-12-10 Impact factor: 5.881